New Delhi, Oct. 6 -- Shionogi has agreed to acquire IntraBio for $2 billion in upfront cash, expanding its rare neurological disease business with AQNEURSA, also known as levacetylleucine. Announced on October 5, 2026, the proposed acquisition follows a recent FDA approval that broadened the medicine's use in a treatment landscape with limited options.

What the IntraBio Acquisition Includes

Shionogi's subsidiary, Shionogi Inc., will purchase all outstanding IntraBio shares, making the Austin, Texas, company a wholly owned subsidiary. Completion is planned between November and December 2026, subject to regulatory clearances and other closing conditions.

The transaction would give Shionogi global intellectual property and commercializati...